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Abstract
In a recent issue of Critical Care, Qiao and colleagues showed in a
rat model of sepsis that dexmedetomidine and midazolam
suppress the generation of pro-inflammatory mediators but the
effects vary between agents. While dexmedetomidine limited
apoptosis to a greater extent than midazolam, both agents
significantly reduced short-term mortality compared with saline.
This study, in addition to those by others, suggests there are
disparate immunomodulating effects between sedatives. Clinical
studies are warranted to investigate whether these effects impact
outcomes of septic patients. Perhaps one day the choice of
sedative in septic patients will not be based solely on sedative
properties but rather immunosedative profiles.
In a recent issue of Critical Care, Qiao and colleagues [1]
used a cecal ligation model of sepsis to compare the
immunomodulating effects of dexmedetomidine, midazolam,
and saline (placebo). They demonstrated that, over the
course of an 8-hour infusion period, both sedatives signifi-
cantly reduced the production of tumor necrosis factor-alpha
(TNF-α) but that only dexmedetomidine decreased interleukin
(IL)-6 generation. Similarly, dexmedetomidine limited the
splenic expression of caspase 3, a marker of apoptosis, to a
greater extent than midazolam when compared with placebo.
Mortality rates at 24 hours were similar between sedatives
and were significantly reduced compared with placebo.
In vitro and other animal studies of sepsis have shown that
dexmedetomidine suppresses the expression of cyclo-
oxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS),
TNF-α, IL-1β, IL-6, and interferon-gamma (IFN-γ) [2-4]. These
effects appear to be dose-dependent across the range of
commonly used doses and time-dependent in that greater
anti-inflammatory effects are observed if dexmedetomidine is
started earlier after the exposure of endotoxin [3-5]. Reversal
of these effects occurs when alpha-2 antagonists are
concomitantly administered with dexmedetomidine, suggest-
ing that neural-immune modulation involving alpha-2 stimu-
lation is essential to the anti-inflammatory mechanism of
dexmedetomidine [2]. Of note, iNOS expression is enhanced
at supratherapeutic concentrations of dexmedetomidine and
further suggests that alpha-2 selectivity contributes to the
anti-inflammatory action of dexmedetomidine [2]. Perhaps
most intriguing is that hemodynamic stability and short-term
survival rate emulate the dose-dependent and time-
dependent anti-inflammatory effects of dexmedetomidine in
these animal models of sepsis [3-5].
Benzodiazepines have also demonstrated dose-dependent
suppression of COX-2, iNOS, and pro-inflammatory
mediators in models of sepsis [6-10]. These studies suggest
that the mechanism is mediated by inhibiting nuclear
translocation of nuclear factor-kappa-B, reducing phos-
phorylation of p38 mitogen-activated protein, and stabilizing
mast cells. The results of animal studies have shown
conflicting outcomes with benzodiazepines, in contrast to
dexmedetomidine, as survival rate is lower and organ
function unaffected but bactericidal effect enhanced with
benzodiazepine therapy [10].
Few studies have investigated the immunomodulating effects
of sedatives in critically ill patients. In surgical patients,
dexmedetomidine 0.2 to 2.5 μg/kg per hour reduced IL-6
over the course of an 8-hour period to a greater extent than
propofol 1 to 3 mg/kg per hour [11]. Also in surgical patients,
midazolam 0.02 to 0.06 mg/kg per hour reduced TNF-α,
IL-1β, and IFN-γ after 48 hours whereas propofol 0.5 to
1.5 mg/kg per hour increased the production of these pro-
inflammatory cytokines [12]. A direct comparison of dex-
medetomidine 0.2 to 2.5 μg/kg per hour and midazolam 0.1
to 0.5 mg/kg per hour in septic patients showed that only
dexmedetomidine suppressed the expression of TNF-α,
IL-1β, and IL-6; however, both agents improved oxygenation
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as assessed by gastric mucosal pH [13]. In a subgroup of 39
septic patients from the MENDS (maximizing efficacy of
targeted sedation and reducing neurological dysfunction)
trial, the risk of dying was lower in the group that received
dexmedetomidine compared with lorazepam (hazard ratio =
0.3, 95% confidence interval = 0.1 to 0.9, P = 0.036) [14].
The SEDCOM (Safety and Efficacy of Dexmedetomidine
Compared With Midazolam) study compared dexmedeto-
midine and midazolam and reported a lower overall infection
rate in the dexmedetomidine group (10.2% versus 19.7%,
P = 0.02), but this may be attributed to a shorter ventilator
requirement in this group rather than different
immunomodulating properties of the sedatives [15]. Mortality
rates at day 30 were similar between groups.
Should a particular class of sedative be preferred when
sedating the septic patient? At present, the answer to this
question is ‘no’ or at least ‘not yet’. What is evident is that
sedatives have immunomodulating properties and that auto-
nomic activity influences cytokine expression. Indeed, adrener-
gic catecholamines are known to influence immune responses
and the process of inflammation [16]. Animal models of
sedatives in sepsis rarely administered vasopressors for
hemodynamic support, but it is conceivable that a particular
vasopressor-sedative combination may be preferentially
chosen to counterbalance their immunomodulating effects or
enhance a specific effect. Septic patients frequently receive
other immunomodulating therapies, including corticosteroids,
drotrecogin, opioid analgesics, propofol, or immunonutrients
[17,18]. How these agents interact with alpha-2 agonists or
benzodiazepines is unknown, but presumably the use of these
modalities was distributed equally in the few clinical studies
conducted to date. Hypotension is a particular concern of
using an alpha-2 agonist in sepsis. Data from animal studies,
however, demonstrate improved hemodynamic profiles as the
pro-inflammatory process subsides with dexmedetomidine
administration [3-5].
Whether sedatives possess dose-dependent immunomodulat-
ing effects has not been studied in critically ill patients. Animal
data, however, suggest that dexmedetomidine may possess
an optimal dose for its immunomodulating activity [3-5]. This
dose would likely vary between patients and within the same
patient over time. The logical question if such a dose does
exist is what to do if additional sedation is required. Or is this,
in addition to shorter ventilator requirements and improved
neurologic recovery, justification for minimizing sedation?
Another intriguing observation is the time-dependent immuno-
modulating effect of dexmedetomidine because, in theory,
dexmedetomidine may be an ideal sedative to initiate in early
sepsis but other sedatives may be preferred later [3-5]. Does
this necessitate changing the sedative agent as the sepsis
process progresses? This is not unlike the scenario of the
patient perceived to be unresponsive to a particular antibiotic
who is changed to another class of antibiotic for greater
response. Obviously, these queries are speculative. The
studies conducted to date in animal models of sepsis show
that there are disparate immunomodulating effects and
possibly therapeutic outcomes between sedatives [1-17].
Perhaps one day the choice of sedative in septic patients will
not be based solely on sedative properties but rather
immunosedative profiles.
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